Erasca Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.55
- Today's High:
- $2.71
- Open Price:
- $2.69
- 52W Low:
- $2.49
- 52W High:
- $10.74
- Prev. Close:
- $2.68
- Volume:
- 422217
Company Statistics
- Market Cap.:
- $497.50 million
- Book Value:
- 2.565
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -19.61%
- Return on Equity TTM:
- -59.07%
Company Profile
Erasca Inc had its IPO on 2021-07-16 under the ticker symbol ERAS.
The company operates in the Healthcare sector and Biotechnology industry. Erasca Inc has a staff strength of 129 employees.
Stock update
Shares of Erasca Inc opened at $2.69 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.55 - $2.71, and closed at $2.57.
This is a -4.1% slip from the previous day's closing price.
A total volume of 422,217 shares were traded at the close of the day’s session.
In the last one week, shares of Erasca Inc have slipped by -0.77%.
Erasca Inc's Key Ratios
Erasca Inc has a market cap of $497.50 million, indicating a price to book ratio of 1.9025 and a price to sales ratio of 0.
In the last 12-months Erasca Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-144838000. The EBITDA ratio measures Erasca Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Erasca Inc’s operating margin was 0% while its return on assets stood at -19.61% with a return of equity of -59.07%.
In Q1, Erasca Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Erasca Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Erasca Inc’s profitability.
Erasca Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.8854. Its price to sales ratio in the trailing 12-months stood at 0.
Erasca Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $467.54 million
- Total Liabilities
- $25.52 million
- Operating Cash Flow
- $14.71 million
- Capital Expenditure
- $21.21 million
- Dividend Payout Ratio
- 0%
Erasca Inc ended 2025 with $467.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $467.54 million while shareholder equity stood at $-514170000.00.
Erasca Inc ended 2025 with $0 in deferred long-term liabilities, $25.52 million in other current liabilities, 15000.00 in common stock, $-514170000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $272.76 million and cash and short-term investments were $389.74 million. The company’s total short-term debt was $3,118,000 while long-term debt stood at $0.
Erasca Inc’s total current assets stands at $397.88 million while long-term investments were $0 and short-term investments were $116.99 million. Its net receivables were $0 compared to accounts payable of $3.35 million and inventory worth $0.
In 2025, Erasca Inc's operating cash flow was $14.71 million while its capital expenditure stood at $21.21 million.
Comparatively, Erasca Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $2.57
- 52-Week High
- $10.74
- 52-Week Low
- $2.49
- Analyst Target Price
- $14
Erasca Inc stock is currently trading at $2.57 per share. It touched a 52-week high of $10.74 and a 52-week low of $10.74. Analysts tracking the stock have a 12-month average target price of $14.
Its 50-day moving average was $2.63 and 200-day moving average was $3.4 The short ratio stood at 17.08 indicating a short percent outstanding of 0%.
Around 2175.4% of the company’s stock are held by insiders while 6562.1% are held by institutions.
Frequently Asked Questions About Erasca Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.